Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma

2015/08/22 by Bhishamjit S. Chera, Robert J. Amdur, Joel Tepper +19 · 4 citations
Medicine · #Esophageal Cancer Research and Treatment #Head and Neck Cancer Studies #Head and Neck Surgical Oncology

paper · doi:10.1016/j.ijrobp.2015.08.033

openalex publication_date 2015/08/22 · crossref created 2015/08/22 · crossref issued 2015/12/01 · crossref published 2015/12/01 · crossref published-print 2015/12/01 · crossref deposited 2025/05/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/03 · crossref indexed 2026/08/03

Citations

• Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial
• Transoral laser microsurgery as primary treatment for advanced‐stage oropharyngeal cancer: A united states multicenter study
• Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
• Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
• Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
• Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
• Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
• Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer
• Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Cited by

• Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?
• Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma
• Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
• HPV-positive oropharyngeal cancer [wikipedia]